2013/1 GaBI Journal Table of Contents


Editor’s Letter

Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal

Letters to the Editor

The ethics of biosimilars

Austria increases dialogue in order to involve physicians more with biosimilars


Health authority perspective on biosimilars


The case for biosimilars–a payer’s perspective

Original Research

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation

Review Article

Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act

Current status of biopharmaceuticals in Iran’s pharmaceutical market

Biosimilars in the European market


The future of biological therapy: a pathway forward for biosimilars


PMDA update: the current situation and future directions


New CHMP guideline on immunogenicity of monoclonal antibodies

EORTC continues to support the appropriate treatment of adult patients with G-CSF to prevent febrile neutropenia: guideline updates

Abstracted Scientific Content

Alleviating concerns around generic antiepileptic medications

Pharma News

‘Similar biologics’ approved and marketed in India

For Patients

IAPO launched the Patient-Centred Healthcare Indicators Review


Source URL: https://gabi-journal.net/2400.html

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048